2015ASCO乳腺癌内分泌治疗与骨保护进展陈占红概述.ppt

谢谢您的关注！！ 陈占红 2015.6.21 Phase III Trials Endocrine Therapy +/- Bevacizumab (open-label) Presented By Joseph Sparano at 2015 ASCO Annual Meeting 主要数据截止期后，进展由研究者确定 氟维司群 500mg n=102 阿那曲唑 1mg n=103 进展患者数（%） 63 (61.8) 79 (76.7) 中位时间 （月） 23.4 13.1 0 6 12 18 24 30 36 42 48 0.0 0.2 0.4 0.6 0.8 1.0  无进展存活患者比例 时间（月） 102 74 65 52 45 34 20 6 0 103 69 55 39 30 21 8 2 0 氟维司群 500mg 阿那曲唑 1mg HR=0.66 95% CI (0.47, 0.92) p=0.01 氟维司群 500 mg 阿那曲唑 1 mg 风险患者数： * 0 12 18 42 48 月 36 30 24 6 至进展时间（TTP 随访分析） Robertson et al. Breast Cancer Res Treat 2012 3104P2003-2006 * 不同类型双磷酸盐辅助性全身治疗乳腺癌无显著差异，尽管毒性有别，但是各组间差异较小 狄诺塞麦辅助治疗可显著降低接受 AI 治疗的绝经后乳腺癌患者的骨折次数并提高患者骨密度且安全性良好 * * IBIS-II,MAP3 * Treatment Summary Presented By Nicholas Turner at 2015 ASCO Annual Meeting 治疗情况汇总 Primary Endpoint: PFS (ITT Population) Presented By Nicholas Turner at 2015 ASCO Annual Meeting Slide 16 Presented By Nicholas Turner at 2015 ASCO Annual Meeting Summary of Key Secondary Efficacy Endpoints Presented By Nicholas Turner at 2015 ASCO Annual Meeting 次要疗效终点汇总 Adverse Events—All Cause Presented By Nicholas Turner at 2015 ASCO Annual Meeting 不良反应 Summary of Adverse Events Presented By Nicholas Turner at 2015 ASCO Annual Meeting 总结 Palbociclib联合氟维司群较安慰剂联合氟维司群治疗能明显提高之前内分泌治疗进展的HR+/ HER2-晚期乳腺癌的PFS HR=0.422 （95% CI， 0.318 到 0.560；P＜0.000001） 在所有提前预设的亚组均能看到获益 安全性能耐受 Palbociclib联合氟维司群是治疗之前内分泌治疗进展的患者的有效的治疗方式 内容 LBA500：NSABP B-35关于绝经后DCIS采取“肿块切除+放疗” 常规治疗基础上，内分泌治疗选择TAM和阿那曲唑何者更优？ 1 A501：CALGB40503关于绝经后激素受体阳性乳腺癌一 线选择来曲唑单药或联合贝伐单抗的Ⅲ期临床研究； 2 3 4 LBA502：PALOMA3是对于激素受体阳性晚期乳腺癌内分泌解救选择氟维司群500mg基础加或不加CDK4/6抑制剂palbociclib的Ⅲ期临床研究； A503-504：早期乳腺癌辅助双膦酸盐或地诺单抗（denosumab）治疗Ⅲ期临床研究(S0307和ABCSG-18); Role of Adjuvant Bisphosphonates In Early Breast Cancer Presented By Robert Coleman at 2015 ASCO Annual Meeting Aromatase Inhibitors Result In Increased Bone Loss and Poorer Quality Bone Presented By Robert Coleman at 2015 ASCO Annual Meeting Aromatase Inhibitors Are Associated With An Increased Rate of Fractures Presented By Robert Colem